{"prompt": "['Secondary endpoints:', 'The safety and tolerability of lenvatinib in combination with pembrolizumab have been assessed', 'in the Phase 2 and now Phase 3 trial of these drugs in tandem in metastatic RCC. However, we', 'are seeking to assess their tolerability in the neoadjuvant setting where a patient is being treated', 'with curative intent with the goal of nephrectomy after the completion of study treatment.', 'We hypothesized that the downsizing/downstaging of primary after neoadjuvant treatment has', 'the potential to allow for conversion from radical to partial nephrectomy. Thus, the assessment of', 'any perioperative adverse events such as anemia, bleeding, wound dehiscence, or post-operative', 'pneumonia or pulmonary embolism, among many others, will be important to understand the', 'potential impact this neoadjuvant therapy may have on decreasing surgical morbidity [1].', 'In addition, if tumor burden can be reduced significantly prior to surgery, it is possible that', 'patients may ultimately experience improved DFS and OS as a result. We seek to address', 'outcomes in our Long-Term Follow-up period.', 'Exploratory endpoints:', 'Given that patients enrolled in this trial are being treated with curative intent, it is important to', 'assess how experimental neoadjuvant therapy affects their quality of life, frailty and degree of', 'sarcopenia. Thus, we will be assessing quality of life will be studied using the Functional', 'Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) questionnaire (Appendix', '4), frailty using the Fried Frailty score (Appendix 5), and degree of sarcopenia by assessment of', 'pre-and post-treatment imaging via SliceOmatic v5.0 by TomoVision program.', '4.2.3.2 Biomarker Research', 'Tumor tissue from prior to trial allotment (in the form of archival tissue or new biopsy if', 'archival tissue is not available) compared to post-treatment nephrectomy specimen will', 'be evaluated for assessment of mutations and/or immune markers including PD-1/PD-L1', 'and other relevant biomarkers (e.g. tumor infiltrating lymphocytes, T- cell repertoire,', 'RNA signature profiles). We will also use flow cytometry to assess the phenotypic', 'characteristics of cell populations in the tumor microenvironment and changes occurring', 'throughout the course of neoadjuvant VEGF inhibition and immunotherapy. Tissue will', 'be preserved for future exploratory studies including genomic profiling. Stool sample will', 'be collected for microbiome analysis.', 'Correlative peripheral blood samples will be collected prior to study drug allotment, throughout', 'treatment and post-treatment (both before and after nephrectomy). These samples will be', 'assessed for', 'Page 10', 'Version Date: 05/08/2020']['Circulating tumor DNA (ctDNA) to explore genetic alterations that are present are', 'baseline and/or emerge during treatment', 'Analysis of peripheral blood mononuclear cells (PBMCs) to assess for', 'phenotypic/functional changes in T-cells or myeloid markers during and after treatment', 'Nuclear acid analysis for gene expression profiling', '5.0 METHODOLOGY', '5.1', 'Study Population', '5.1.1 Participant Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria apply:', '1. Patients with a renal mass consistent with a clinical stage > T3Nx or TanyN+ or deemed', 'unresectable by surgeon', '2. Renal cell carcinoma with clear cell component on pre-treatment biopsy of the primary', 'tumor', '3. The subject is > 18 years of age on the day of signing informed consent', '4. The participant (or legally acceptable representative if applicable) provides written', 'informed consent and the willingness and ability to comply with all aspects of the', 'protocol', '5. Have an Eastern Cooperative Oncology Group (ECOG) performance status 2', '6. Have adequate organ function as defined in the following table (Table 1). Specimens', 'must be collected within 72 hours prior to the start of study treatment.', 'Table 1. Adequate Organ Function Laboratory Values', 'System', 'Laboratory Value', 'Hematological/Coagulation', 'Absolute neutrophil count (ANC)', '1500/L', 'Platelets', '100 000/L', 'Hemoglobin', '9.0g/dLa', 'International normalized ratio (INR) OR', '<1.5 X ULN unless participant is receiving', 'prothrombin time (PT)', 'anticoagulant therapy as long as PT or aPTT is', 'Activated partial thromboplastin time (aPTT)', 'within therapeutic range of intended use of', 'anticoagulants', 'Page 11', 'Version Date: 05/08/2020']\n\n###\n\n", "completion": "END"}